Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 871 Präparate · 48256 Quellenpassagen · 124 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Gegenanzeigen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.3 · PDF-Seite 4
HOS-086138 · Präparat HOS-083284
Concomitant medicinal product levels increased or decreased
1-Adrenoreceptor Alfuzosin Increased plasma concentrations of alfuzosin
Antagonist which may lead to severe hypotension (see
section 4.5).
Analgesics Pethidine, Increased plasma concentrations of
propoxyphene norpethidine and propoxyphene. Thereby,
increasing the risk of serious respiratory
depression or haematologic abnormalities, or
other serious adverse effects from these agents.
Antianginal Ranolazine Increased plasma concentrations of ranolazine
which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Anticancer Neratinib Increased plasma concentrations of neratinib
which may increase the potential for serious
and/or life-threatening reactions including
hepatotoxicity (see section 4.5).
Venetoclax Increased plasma concentrations of venetoclax.
Increased risk of tumor lysis syndrome at the
dose initiation and during the dose-titration
phase (see section 4.5).
Antiarrhythmics Amiodarone, bepridil, Increased plasma concentrations of amiodarone,
dronedarone, bepridil, dronedarone, encainide, flecanide,
encainide, flecanide, propafenone, quinidine. Thereby, increasing the
propafenone, quinidine risk of arrhythmias or other serious adverse
reactions from these agents.
Antibiotic Fusidic Acid Increased plasma concentrations of fusidic acid
and ritonavir.
Anti-gout Colchicine Potential for serious and/or life-threatening
reactions in patients with renal and/or hepatic
impairment (see sections 4.4 and 4.5).
Antihistamines Astemizole, Increased plasma concentrations of astemizole
terfenadine and terfenadine. Thereby, increasing the risk of
serious arrhythmias from these agents.
Antipsychotics/ Lurasidone Increased plasma concentrations of lurasidone
Neuroleptics which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Clozapine, pimozide Increased plasma concentrations of clozapine
and pimozide. Thereby, increasing the risk of
serious haematologic abnormalities, or other
serious adverse effects from these agents.
Quetiapine Increased plasma concentrations of quetiapine
which may lead to coma. The concomitant
administration with quetiapine is
contraindicated (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): encainide (HOS-086145) propafenone (HOS-084530) quinidine (HOS-085593) fusidic acid (HOS-086146) colchicine (HOS-086147) astemizole (HOS-085608) terfenadine (HOS-085607) lurasidone (HOS-086148) clozapine (HOS-086149) pimozide (HOS-085600) quetiapine (HOS-086150) bepridil (HOS-085612) dronedarone (HOS-086144) alfuzosin (HOS-086139) lead (HOS-085592) propoxyphene (HOS-086140) ranolazine (HOS-086141) neratinib (HOS-086142) venetoclax (HOS-086143) amiodarone (HOS-085596)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage f9fe97979894eedcce9660008265f9fc818cdb3984974bb2555b6c5e5869e4e5 · Zeichen 902–5292 im Abschnitt
Gegenanzeigen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 35–36
HOS-086388 · Präparat HOS-083284
35
Analgesics Pethidine, Increased plasma concentrations of
propoxyphene norpethidine and propoxyphene. Thereby,
increasing the risk of serious respiratory
depression or haematologic abnormalities, or
other serious adverse effects from these agents.
Antianginal Ranolazine Increased plasma concentrations of ranolazine
which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Anticancer Neratinib Increased plasma concentrations of neratinib
which may increase the potential for serious
and/or life-threatening reactions including
hepatotoxicity (see section 4.5).
Venetoclax Increased plasma concentrations of venetoclax.
Increased risk of tumor lysis syndrome at the
dose initiation and during the dose-titration
phase (see section 4.5).
Antiarrhythmics Amiodarone, bepridil, Increased plasma concentrations of amiodarone,
dronedarone, bepridil, dronedarone, encainide, flecainide,
encainide, flecainide, propafenone, quinidine. Thereby, increasing
propafenone, quinidine the risk of arrhythmias or other serious adverse
effects from these agents.
Antibiotic Fusidic Acid Increased plasma concentrations of fusidic acid
and ritonavir.
Antihistamines Astemizole, Increased plasma concentrations of astemizole
terfenadine and terfenadine. Thereby, increasing the risk of
serious arrhythmias from these agents.
Anti-gout Colchicine Potential for serious and/or life-threatening
reactions in patients with renal and/or hepatic
impairment (see sections 4.4 and 4.5).
Antipsychotics/ Lurasidone Increased plasma concentrations of lurasidone
Neuroleptics which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Clozapine, pimozide Increased plasma concentrations of clozapine
and pimozide. Thereby, increasing the risk of
serious haematologic abnormalities, or other
serious adverse effects from these agents.
Quetiapine Increased plasma concentrations of quetiapine
which may lead to coma. The concomitant
administration with quetiapine is
contraindicated (see section 4.5).
Ergot Derivatives Dihydroergotamine, Increased plasma concentrations of ergot
ergonovine, derivatives leading to acute ergot toxicity,
ergotamine, including vasospasm and ischaemia.
methylergonovine
GI motility agent Cisapride Increased plasma concentrations of cisapride.
Thereby, increasing the risk of serious
arrhythmias from this agent.
Lipid-modifying agents
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lead (HOS-085592) dihydroergotamine (HOS-086152) ergonovine (HOS-086153) ergotamine (HOS-086154) methylergonovine (HOS-086155) cisapride (HOS-085610) quinidine (HOS-085593) fusidic acid (HOS-086146) astemizole (HOS-085608) terfenadine (HOS-085607) colchicine (HOS-086147) lurasidone (HOS-086148) clozapine (HOS-086149) pimozide (HOS-085600) quetiapine (HOS-086150) propoxyphene (HOS-086140) ranolazine (HOS-086141) neratinib (HOS-086142) venetoclax (HOS-086143) amiodarone (HOS-085596) bepridil (HOS-085612) dronedarone (HOS-086144) encainide (HOS-086145) flecainide (HOS-086203) propafenone (HOS-084530)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage f76b82bf2af9e33f5778d35af3ff4a8ea2ea8d392666af7950204db67ec4ac88 · Zeichen 1234–5743 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 17
HOS-086259 · Präparat HOS-083284
Anti-infectives
Fusidic Acid Ritonavir co-administration is likely to result in increased plasma concentrations of
both fusidic acid and ritonavir and is therefore contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fusidic acid (HOS-086146)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 412349d53b43e7fb6a8ab6ec75c0337520af0d093ee1cb7f6b03ce1ce4c480e6 · Zeichen 29917–30178 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 49
HOS-086444 · Präparat HOS-083284
Anti-infectives
Fusidic Acid Ritonavir co-administration is likely to result in increased plasma concentrations of both
fusidic acid and ritonavir and is therefore contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fusidic acid (HOS-086146)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 49ddf8d659730b5c699fa96449367bb2542580c9d4c0aa542b14001aba4aad6f · Zeichen 30954–31215 im Abschnitt
Gegenanzeigen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.3 · PDF-Seite 5
HOS-108791 · Präparat HOS-093083
Concomitant medicinal product levels increased
Alpha1-adrenoreceptor Alfuzosin Increased plasma concentrations of
antagonist alfuzosin which may lead to severe
hypotension. The concomitant
administration with alfuzosin is
contraindicated (see section 4.5).
Antianginal Ranolazine Increased plasma concentrations of
ranolazine which may increase the
potential for serious and/or life-
threatening reactions (see section 4.5).
Antiarrhythmics Amiodarone, dronedarone Increased plasma concentrations of
amiodarone and dronedarone. Thereby,
increasing the risk of arrhythmias or
other serious adverse reactions (see
section 4.5).
Antibiotic Fusidic Acid Increased plasma concentrations of
fusidic acid. The concomitant
administration with fusidic acid is
contraindicated in dermatological
infections (see section 4.5).
Anticancer Neratinib Increased plasma concentrations of
neratinib which may increase the
potential for serious and/or
life-threatening reactions (see section
4.5).
Venetoclax Increased plasma concentrations of
venetoclax. Increased risk of tumor lysis
syndrome at the dose initiation and
during the ramp-up phase (see section
4.5).
Anti-gout Colchicine Increased plasma concentrations of
colchicine. Potential for serious and/or
life-threatening reactions in patients with
renal and/or hepatic impairment (see
sections 4.4 and 4.5).
Antihistamines Astemizole, terfenadine Increased plasma concentrations of
astemizole and terfenadine. Thereby,
increasing the risk of serious
arrhythmias from these agents (see
section 4.5).
Antipsychotics/ Lurasidone Increased plasma concentrations of
Neuroleptics lurasidone which may increase the
potential for serious and/or life-
threatening reactions (see section 4.5).
Pimozide Increased plasma concentrations of
pimozide. Thereby, increasing the risk
of serious haematologic abnormalities,
or other serious adverse effects from this
agent (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dronedarone (HOS-086144) fusidic acid (HOS-086146) neratinib (HOS-086142) venetoclax (HOS-086143) colchicine (HOS-086147) astemizole (HOS-085608) terfenadine (HOS-085607) lurasidone (HOS-086148) pimozide (HOS-085600) alfuzosin (HOS-086139) lead (HOS-085592) ranolazine (HOS-086141) amiodarone (HOS-085596)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 3af5f7da19ec49492414676af6b40d10b1389f87518dc00840ff964623d97870 · Zeichen 617–4755 im Abschnitt
Gegenanzeigen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 42
HOS-108987 · Präparat HOS-093083
Concomitant medicinal product levels increased
Alpha1- Alfuzosin Increased plasma concentrations of
adrenoreceptor alfuzosin which may lead to severe
antagonist hypotension. The concomitant
administration with alfuzosin is
contraindicated (see section 4.5).
Antianginal Ranolazine Increased plasma concentrations of
ranolazine which may increase the
potential for serious and/or life-
threatening reactions (see section 4.5).
Antiarrhythmics Amiodarone, dronedarone Increased plasma concentrations of
amiodarone and dronedarone. Thereby,
increasing the risk of arrhythmias or
other serious adverse reactions (see
section 4.5).
Antibiotic Fusidic Acid Increased plasma concentrations of
fusidic acid. The concomitant
administration with fusidic acid is
contraindicated in dermatological
infections (see section 4.5).
Anticancer Neratinib Increased plasma concentrations of
neratinib which may increase the
potential for serious and/or
life-threatening reactions (see section
4.5).
Venetoclax Increased plasma concentrations of
venetoclax. Increased risk of tumor
lysis syndrome at the dose initiation
and during the ramp-up phase (see
section 4.5).
Anti-gout Colchicine Increased plasma concentrations of
colchicine. Potential for serious and/or
life-threatening reactions in patients
with renal and/or hepatic impairment
(see sections 4.4 and 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ranolazine (HOS-086141) amiodarone (HOS-085596) dronedarone (HOS-086144) fusidic acid (HOS-086146) neratinib (HOS-086142) venetoclax (HOS-086143) colchicine (HOS-086147) alfuzosin (HOS-086139) lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 9293fe9ecfe32956533c5b772cc23612b4a6e3a500aeb3b328481fd78b786272 · Zeichen 583–3923 im Abschnitt
Gegenanzeigen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 77
HOS-109061 · Präparat HOS-093083
Concomitant medicinal product levels increased
Alpha1-adrenoreceptor Alfuzosin Increased plasma concentrations of
antagonist alfuzosin which may lead to severe
hypotension. The concomitant
administration with alfuzosin is
contraindicated (see section 4.5).
Antianginal Ranolazine Increased plasma concentrations of
ranolazine which may increase the
potential for serious and/or life-
threatening reactions (see section 4.5).
Antiarrhythmics Amiodarone, dronedarone Increased plasma concentrations of
amiodarone and dronedarone. Thereby,
increasing the risk of arrhythmias or other
serious adverse reactions (see section 4.5).
Antibiotic Fusidic Acid Increased plasma concentrations of fusidic
acid. The concomitant administration with
fusidic acid is contraindicated in
dermatological infections (see section
4.5).
Anticancer Neratinib Increased plasma concentrations of
neratinib which may increase the potential
for serious and/or life-threatening
reactions (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ranolazine (HOS-086141) amiodarone (HOS-085596) dronedarone (HOS-086144) fusidic acid (HOS-086146) neratinib (HOS-086142) alfuzosin (HOS-086139) lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 422bc2611cbcfafe8056f19a35bbcf976c0ce7cedb0696fe265110f54c2451df · Zeichen 589–2890 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 17–18
HOS-108900 · Präparat HOS-093083
17
Anti-gout agents
Colchicine single dose Colchicine: Concomitant administration of
AUC: ↑ 3-fold Kaletra with colchicine in patients
(Ritonavir 200 mg twice Cmax: ↑ 1.8-fold with renal and/or hepatic
daily) Due to P-gp and/or CYP3A4 impairment is contraindicated due
inhibition by ritonavir. to a potential increase of
colchicine-related serious and/or
life-threatening reactions such as
neuromuscular toxicity (including
rhabdomyolysis) (see sections 4.3
and 4.4). A reduction in colchicine
dosage or an interruption of
colchicine treatment is
recommended in patients with
normal renal or hepatic function if
treatment with Kaletra is required.
Refer to colchicine prescribing
information.
Antihistamines
Astemizole Serum concentrations may be Concomitant administration of
Terfenadine increased due to CYP3A Kaletra and astemizole and
inhibition by lopinavir/ritonavir. terfenadine is contraindicated as it
may increase the risk of serious
arrhythmias from these agents (see
section 4.3).
Anti-infectives
Fusidic acid Fusidic acid: Concomitant administration of
Concentrations may be increased Kaletra with fusidic acid is contra-
due to CYP3A inhibition by indicated in dermatological
lopinavir/ritonavir. indications due to the increased
risk of adverse events related to
fusidic acid, notably
rhabdomyolysis (see section 4.3).
When used for osteo-articular
infections, where the co-
administration is unavoidable,
close clinical monitoring for
muscular adverse events is
strongly recommended (see section
4.4).
Antimycobacterials
Bedaquiline Bedaquiline: Due to the risk of bedaquiline
(single dose) AUC: ↑ 22% related adverse events, the
Cmax: ↔ combination of bedaquiline and
(Lopinavir/ritonavir Kaletra should be avoided. If the
400/100 mg BID, multiple A more pronounced effect on benefit outweighs the risk,
dose) bedaquiline plasma exposures co-administration of bedaquiline
may be observed during with Kaletra must be done with
prolonged co-administration with caution. More frequent
lopinavir/ritonavir. electrocardiogram monitoring and
monitoring of transaminases is
CYP3A4 inhibition likely due to recommended (see section 4.4 and
lopinavir/ritonavir. refer to the bedaquiline SmPC).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fusidic acid (HOS-086146) bedaquiline (HOS-086268) colchicine (HOS-086147) astemizole (HOS-085608) terfenadine (HOS-085607)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage f0063cdfed3d4b44f9ebbe33645572935b60d76cab70c9d2b49e5bc05279da2c · Zeichen 30589–35272 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 53–54
HOS-109013 · Präparat HOS-093083
53
benefit/risk to patient justifies the use
of voriconazole.
Anti-gout agents
Colchicine single dose Colchicine: Concomitant administration of
AUC: ↑ 3-fold Kaletra with colchicine in patients
(Ritonavir 200 mg Cmax: ↑ 1.8-fold with renal and/or hepatic impairment
twice-daily) Due to P-gp and/or CYP3A4 is contraindicated due to a potential
inhibition by ritonavir. increase of colchicine-related serious
and/or life-threatening reactions such
as neuromuscular toxicity (including
rhabdomyolysis) (see sections 4.3 and
4.4). A reduction in colchicine
dosage or an interruption of
colchicine treatment is recommended
in patients with normal renal or
hepatic function if treatment with
Kaletra is required. Refer to
colchicine prescribing information.
Antihistamines
Astemizole Serum concentrations may be Concomitant administration of
Terfenadine increased due to CYP3A Kaletra and astemizole and
inhibition by lopinavir/ritonavir. terfenadine is contraindicated as it
may increase the risk of serious
arrhythmias from these agents (see
section 4.3).
Anti-infectives
Fusidic acid Fusidic acid: Concomitant administration of
Concentrations may be increased Kaletra with fusidic acid is contra-
due to CYP3A inhibition by indicated in dermatological
lopinavir/ritonavir. indications due to the increased risk
of adverse events related to fusidic
acid, notably rhabdomyolysis (see
section 4.3). When used for osteo-
articular infections, where the co-
administration is unavoidable, close
clinical monitoring for muscular
adverse events is strongly
recommended (see section 4.4).
Antimycobacterials
Bedaquiline Bedaquiline: Due to the risk of bedaquiline related
(single dose) AUC: ↑ 22% adverse events, the combination of
Cmax: ↔ bedaquiline and Kaletra should be
(Lopinavir/ritonavir avoided. If the benefit outweighs the
400/100 mg BID, A more pronounced effect on risk, co-administration of bedaquiline
multiple dose) bedaquiline plasma exposures with Kaletra must be done with
may be observed during caution. More frequent
prolonged co-administration with electrocardiogram monitoring and
lopinavir/ritonavir. monitoring of transaminases is
recommended (see section 4.4 and
CYP3A4 inhibition likely due to refer to the bedaquiline SmPC).
lopinavir/ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): voriconazole (HOS-084524) colchicine (HOS-086147) astemizole (HOS-085608) terfenadine (HOS-085607) fusidic acid (HOS-086146) bedaquiline (HOS-086268)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage cad5366a6fb47c00b40c65b02f661a2f3f24b27d6187e7ce6cfffb83a5f12fd8 · Zeichen 29746–34245 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 89–90
HOS-109089 · Präparat HOS-093083
89
Anti-infectives
Fusidic acid Fusidic acid: Concomitant administration of
Concentrations may be increased Kaletra with fusidic acid is contra-
due to CYP3A inhibition by indicated in dermatological
lopinavir/ritonavir. indications due to the increased risk
of adverse events related to fusidic
acid, notably rhabdomyolysis (see
section 4.3). When used for osteo-
articular infections, where the co-
administration is unavoidable, close
clinical monitoring for muscular
adverse events is strongly
recommended (see section 4.4).
Antimycobacterials
Bedaquiline Bedaquiline: Due to the risk of bedaquiline
(single dose) AUC: ↑ 22% related adverse events, the
Cmax: ↔ combination of bedaquiline and
(Lopinavir/ritonavir Kaletra should be avoided. If the
400/100 mg BID, A more pronounced effect on benefit outweighs the risk,
multiple dose) bedaquiline plasma exposures co-administration of bedaquiline
may be observed during with Kaletra must be done with
prolonged co-administration with caution. More frequent
lopinavir/ritonavir. electrocardiogram monitoring and
monitoring of transaminases is
CYP3A4 inhibition likely due to recommended (see section 4.4 and
lopinavir/ritonavir. refer to the bedaquiline SmPC).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fusidic acid (HOS-086146) bedaquiline (HOS-086268)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 65e6870b925cfa041fafca521b5fcbe7c52c38b5b0bbc4488f37222ae0fa46b7 · Zeichen 32216–34417 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.